EP1007051A4 - Integrin receptor antagonists - Google Patents

Integrin receptor antagonists

Info

Publication number
EP1007051A4
EP1007051A4 EP98938357A EP98938357A EP1007051A4 EP 1007051 A4 EP1007051 A4 EP 1007051A4 EP 98938357 A EP98938357 A EP 98938357A EP 98938357 A EP98938357 A EP 98938357A EP 1007051 A4 EP1007051 A4 EP 1007051A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
integrin receptor
integrin
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98938357A
Other languages
German (de)
French (fr)
Other versions
EP1007051A1 (en
Inventor
Dirk Heerding
James Martin Samanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1007051A1 publication Critical patent/EP1007051A1/en
Publication of EP1007051A4 publication Critical patent/EP1007051A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP98938357A 1997-08-04 1998-08-04 Integrin receptor antagonists Withdrawn EP1007051A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5470397P 1997-08-04 1997-08-04
US54703P 1997-08-04
US6352697P 1997-10-29 1997-10-29
US63526P 1997-10-29
PCT/US1998/016246 WO1999006049A1 (en) 1997-08-04 1998-08-04 Integrin receptor antagonists

Publications (2)

Publication Number Publication Date
EP1007051A1 EP1007051A1 (en) 2000-06-14
EP1007051A4 true EP1007051A4 (en) 2001-08-29

Family

ID=26733371

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98938357A Withdrawn EP1007051A4 (en) 1997-08-04 1998-08-04 Integrin receptor antagonists

Country Status (5)

Country Link
EP (1) EP1007051A4 (en)
JP (1) JP2001511452A (en)
AU (1) AU8689798A (en)
CA (1) CA2298544A1 (en)
WO (1) WO1999006049A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2727746A1 (en) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
ES2288040T3 (en) * 1998-12-18 2007-12-16 Bristol-Myers Squibb Pharma Company ANTIGONIST MEDICINES OF VITRONECTINE RECEPTOR.
AU2371400A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
CO5180550A1 (en) * 1999-04-19 2002-07-30 Smithkline Beecham Corp FAB I INHIBITORS
AU6523200A (en) * 1999-08-06 2001-03-05 Smithkline Beecham Corporation Vitronectin receptor antagonists useful for the treatment of strokes
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10028575A1 (en) * 2000-06-14 2002-03-14 Basf Ag integrin
DE10039998A1 (en) * 2000-08-11 2002-02-21 Basf Ag New substituted diareno-azepine derivatives as integrin ligands
DE10027514A1 (en) * 2000-06-06 2002-01-03 Basf Ag Ligands of integrin receptors
WO2001056995A1 (en) 2000-01-18 2001-08-09 Nuerogen Corporation Substituted imidazoles as selective modulators of bradykinin b2 receptors
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
US20040136949A1 (en) 2001-04-24 2004-07-15 Matthias Grell Combination therapy using anti-angiogenic agents and tnf alpha
EP2428226A1 (en) 2001-10-22 2012-03-14 The Scripps Research Institute Antibody targeting compounds
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
MX2009007597A (en) 2007-01-18 2009-07-22 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer.
US9345739B2 (en) 2007-11-08 2016-05-24 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
JP5359879B2 (en) 2007-11-16 2013-12-04 宇部興産株式会社 Benzazepinone compounds
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
BRPI1011206A2 (en) 2009-05-25 2016-03-15 Merck Patent Gmbh continuous administration of integrin ligands to treat cancer
KR20160147007A (en) 2014-05-30 2016-12-21 화이자 인코포레이티드 Carbonitrile derivatives as selective androgen receptor modulators
KR20220115062A (en) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 Pharmaceutical Composition For Treating and Preventing Osteoporosis Comprising Compounds of Chromone Scaffold
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014776A2 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
WO1997001540A1 (en) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000730A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
PL327694A1 (en) * 1995-12-29 1998-12-21 Smithkline Beecham Corp Antagonists of vitronectin receptor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014776A2 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
WO1997001540A1 (en) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
RICHARD M. KEENAN ET AL.: "Discovery of potent nonpeptide Vitronectin Receptor (avb3) Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 15, 18 July 1997 (1997-07-18), pages 2289 - 2292, XP002933333 *
See also references of WO9906049A1 *
WILLIAM E. BONDINELLI ET AL.: "Design of a potent and Orally active Nonpeptide platelet Fibrinogen Receptor (GPIIb/IIIa) Antagonist", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 2, no. 9, 1994, pages 897 - 908, XP000196285 *
WILLIAM H. MILLER ET AL.: "Structure-Activity Relationships in 3-oxo-1,4-benzodiazepine-2-acetic Acid GPIIb/IIIA antagonists. The 2-benzazepine series", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 21, 1996, pages 2481 - 2486, XP004135899 *

Also Published As

Publication number Publication date
CA2298544A1 (en) 1999-02-11
WO1999006049A1 (en) 1999-02-11
EP1007051A1 (en) 2000-06-14
AU8689798A (en) 1999-02-22
JP2001511452A (en) 2001-08-14

Similar Documents

Publication Publication Date Title
EP1047425A4 (en) Integrin receptor antagonists
EP1007051A4 (en) Integrin receptor antagonists
EP1100506A4 (en) Integrin receptor antagonists
EP1105389A4 (en) Integrin receptor antagonists
EP1007026A4 (en) Integrin antagonists
EP0934305A4 (en) Integrin antagonists
EP0880511A4 (en) Integrin receptor antagonists
IL130760A0 (en) Vitronectin receptor antagonists
EP1229910A4 (en) Integrin receptor antagonists
EP1194151A4 (en) Integrin receptor antagonists
HK1031726A1 (en) Thrombin receptor antagonists
IL135028A0 (en) Vitronectin receptor antagonists
IL138245A0 (en) Vitronectin receptor antagonists
EP1027337A4 (en) Integrin receptor antagonists
IL148043A0 (en) Novel integrin receptor antagonists
IL146146A0 (en) Integrin receptor antagonists
IL141163A0 (en) Vitronectin receptor antagonists
ZA986930B (en) Integrin receptor antagonists
ZA9811500B (en) Integrin receptor antagonists
GB9603373D0 (en) Integrin receptor antagonists
IL119820A0 (en) Integrin receptor antagonists
ZA988562B (en) Vitronectin receptor antagonists
ZA9610690B (en) Integrin receptor antagonists.
GB9811283D0 (en) Vironectin receptor antagonists
ZA964195B (en) Integrin receptor antagonists.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20010712

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/55 A, 7C 07D 223/16 B, 7C 07D 243/14 B, 7C 07D 267/14 B, 7C 07D 281/10 B, 7C 07D 401/14 B, 7C 07D 403/12 B

17Q First examination report despatched

Effective date: 20021023

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040720